欧洲药品管理局EMA批准了首例基因疗法药物:荷兰uniQure公司研发的Glybera药物,用于治疗脂蛋白脂酶缺乏(lipoprotein lipase deficiency )。EMA对Glybera的推荐上市建议对于基因治疗领域而言是个极大的进步,也是基因治疗领域的先河,这将有助于其他基因治疗方法的陆续面世。 据路透社媒体最新资讯,上周五时,欧洲药品管理局EMA推荐...
EMA Starts Formal Review Of Glybera(R) DossierAnna Ohlden
药融云数据www.pharnexcloud.com; FDA/EMA/PMDA; 相关公司公开披露(正文图片均来自企业官方,除非另有说明); https://www.xenon-pharma.com/; https://newsinteractives.cbc.ca/longform/glybera; https://www.wired.com/2017/04/the-cure-for-pain/; https://investor.xenon-pharma.com/news-releases/news-...
AMT Submits Responses To Day 120 Questions To EMA As Part Of The Review Process For Glybera(R)Anna Ohlden
FDA/EMA/PMDA; 相关公司公开披露(正文图片均来自企业官方,除非另有说明); https://www.xenon-pharma.com/; https://newsinteractives.cbc.ca/longform/glybera; https://www.wired.com/2017/04/the-cure-for-pain/; https://investor.xenon-pharma.com/news-releases/news-release-details/xenon-pharmaceutical...
AMT Submits Its Lead Product Glybera(R) Application For Marketing Authorisation Application To EMAAnna Ohlden